Quality of Life in Hidradenitis Suppurativa: An Update.

Pavel V Chernyshov,Andrew Y Finlay,Thrasyvoulos Tzellos,Francesca Sampogna,Servando E Marron,Christos C Zouboulis,Sergey V Zemskov,Francoise Poot,Lucia Tomas-Aragones,Damiano Abeni,Jacek C Szepietowski

doi:10.3390/ijerph18116131

Abstract

Knowledge on hidradenitis suppurativa/acne inversa (HS) is rapidly increasing. HS has a profound impact on patients and their family life. Several factors, such as comorbidities, unemployment and HS severity, make this impact even more severe. The most widely used instrument to measure this impact is the dermatology-specific DLQI. We also identified six HS-specific health-related quality of life (HRQoL) instruments. Of them, HIDRAdisk, HSIA, HiSQOL and HSQoL-24 are better validated but there is still lack of experience of its use. Several treatment methods showed positive effect on patients’ HRQoL. Surgery remains a method with a substantial positive effect on HRQoL. Several studies confirming a positive effect of adalimumab on the HRQoL of patients with HS were published during the last three years. Data on the influence of several other biologics on HRQoL of HS patients are controversial or based on studies with a small number of patients.

Highlights

Knowledge about hidradenitis suppurativa/acne inversa (HS) is rapidly increasing.Following the widely accepted Dessauer definition and the establishment of simple but highly accurate diagnostic criteria for earlier recognition of the disease [1], a resolution of the contradictory epidemiological data has been achieved [2] and a practical framework to optimise therapy has been proposed [3]
The European Academy of Dermatology and Venereology (EADV) Task Forces (TFs) on quality of life (QoL) and Patient Oriented Outcomes recommends using the word “quimp” [28] in routine clinical work and research [29] and this word is used in this article
There has been some initial validation of HIDRAdisk, HSIA, HiSQOL and HSQoL-24, but there is still little experience of their use

Summary

Introduction

Knowledge about hidradenitis suppurativa/acne inversa (HS) is rapidly increasing. Following the widely accepted Dessauer definition and the establishment of simple but highly accurate diagnostic criteria for earlier recognition of the disease [1], a resolution of the contradictory epidemiological data has been achieved [2] and a practical framework to optimise therapy has been proposed [3]. Sophisticated molecular studies have achieved a better understanding of HS pathophysiology [4], including the identification of relevant molecular expression patterns, which may allow the possibility of bringing personalised medicine to HS management [5]. There are novel validated criteria for severity classification, such as the International Hidradenitis Suppurativa Severity Score. System (IHS4) [6], and robust clinical outcome measures that allow better monitoring of.

Objectives

Methods

Discussion

Conclusion